- Home
- PALI vs SCTX Comparison
PALI vs SCTX Comparison
Compare PALI & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | SCTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.7M | 330.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PALI | SCTX |
|---|---|---|
| Price | $1.91 | $19.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $11.29 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 349.8K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $260,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1500.39 | N/A |
| 52 Week Low | $0.55 | $17.31 |
| 52 Week High | $2.86 | $23.76 |
Technical Indicators
Market Signals| Indicator | PALI | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 40.16 |
| Support Level | $1.80 | N/A |
| Resistance Level | $2.19 | N/A |
| Average True Range (ATR) | 0.12 | 2.75 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 9.72 | 48.72 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.